Cargando…

Severe varicella-zoster virus pneumonia: a multicenter cohort study

BACKGROUND: Pneumonia is a dreaded complication of varicella-zoster virus (VZV) infection in adults; however, the data are limited. Our objective was to investigate the clinical features, management, and outcomes of critically ill patients with VZV-related community-acquired pneumonia (VZV-CAP). MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirouse, Adrien, Vignon, Philippe, Piron, Prescillia, Robert, René, Papazian, Laurent, Géri, Guillaume, Blanc, Pascal, Guitton, Christophe, Guérin, Claude, Bigé, Naïke, Rabbat, Antoine, Lefebvre, Aurélie, Razazi, Keyvan, Fartoukh, Muriel, Mariotte, Eric, Bouadma, Lila, Ricard, Jean-Damien, Seguin, Amélie, Souweine, Bertrand, Moreau, Anne-Sophie, Faguer, Stanislas, Mari, Arnaud, Mayaux, Julien, Schneider, Francis, Stoclin, Annabelle, Perez, Pierre, Maizel, Julien, Lafon, Charles, Ganster, Frédérique, Argaud, Laurent, Girault, Christophe, Barbier, François, Lecuyer, Lucien, Lambert, Jérôme, Canet, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463395/
https://www.ncbi.nlm.nih.gov/pubmed/28592328
http://dx.doi.org/10.1186/s13054-017-1731-0
_version_ 1783242700271648768
author Mirouse, Adrien
Vignon, Philippe
Piron, Prescillia
Robert, René
Papazian, Laurent
Géri, Guillaume
Blanc, Pascal
Guitton, Christophe
Guérin, Claude
Bigé, Naïke
Rabbat, Antoine
Lefebvre, Aurélie
Razazi, Keyvan
Fartoukh, Muriel
Mariotte, Eric
Bouadma, Lila
Ricard, Jean-Damien
Seguin, Amélie
Souweine, Bertrand
Moreau, Anne-Sophie
Faguer, Stanislas
Mari, Arnaud
Mayaux, Julien
Schneider, Francis
Stoclin, Annabelle
Perez, Pierre
Maizel, Julien
Lafon, Charles
Ganster, Frédérique
Argaud, Laurent
Girault, Christophe
Barbier, François
Lecuyer, Lucien
Lambert, Jérôme
Canet, Emmanuel
author_facet Mirouse, Adrien
Vignon, Philippe
Piron, Prescillia
Robert, René
Papazian, Laurent
Géri, Guillaume
Blanc, Pascal
Guitton, Christophe
Guérin, Claude
Bigé, Naïke
Rabbat, Antoine
Lefebvre, Aurélie
Razazi, Keyvan
Fartoukh, Muriel
Mariotte, Eric
Bouadma, Lila
Ricard, Jean-Damien
Seguin, Amélie
Souweine, Bertrand
Moreau, Anne-Sophie
Faguer, Stanislas
Mari, Arnaud
Mayaux, Julien
Schneider, Francis
Stoclin, Annabelle
Perez, Pierre
Maizel, Julien
Lafon, Charles
Ganster, Frédérique
Argaud, Laurent
Girault, Christophe
Barbier, François
Lecuyer, Lucien
Lambert, Jérôme
Canet, Emmanuel
author_sort Mirouse, Adrien
collection PubMed
description BACKGROUND: Pneumonia is a dreaded complication of varicella-zoster virus (VZV) infection in adults; however, the data are limited. Our objective was to investigate the clinical features, management, and outcomes of critically ill patients with VZV-related community-acquired pneumonia (VZV-CAP). METHODS: This was an observational study of patients with VZV-CAP admitted to 29 intensive care units (ICUs) from January 1996 to January 2015. RESULTS: One hundred and two patients with VZV-CAP were included. Patients were young (age 39 years (interquartile range 32–51)) and 53 (52%) were immunocompromised. Time since respiratory symptom onset was 2 (1–3) days. There was a seasonal distribution of the disease, with more cases during spring and winter time. All but four patients presented with typical skin rash on ICU admission. Half the patients received mechanical ventilation within 1 (1–2) day following ICU admission (the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO(2)/FiO(2)) = 150 (80–284), 80% with acute respiratory distress syndrome (ARDS)). Sequential Organ Failure Assessment (SOFA) score on day 1 (odds ratio (OR) 1.90 (1.33–2.70); p < 0.001), oxygen flow at ICU admission (OR 1.25 (1.08–1.45); p = 0.004), and early bacterial co-infection (OR 14.94 (2.00–111.8); p = 0.009) were independently associated with the need for mechanical ventilation. Duration of mechanical ventilation was 14 (7–21) days. ICU and hospital mortality rates were 17% and 24%, respectively. All patients were treated with aciclovir and 10 received adjunctive therapy with steroids. Compared to 60 matched steroid-free controls, patients treated with steroids had a longer mechanical ventilation duration, ICU length of stay, and a similar hospital mortality, but experienced more ICU-acquired infections. CONCLUSIONS: Severe VZV-CAP is responsible for an acute pulmonary involvement associated with a significant morbidity and mortality. Steroid therapy did not influence mortality, but increased the risk of superinfection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-017-1731-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5463395
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54633952017-06-08 Severe varicella-zoster virus pneumonia: a multicenter cohort study Mirouse, Adrien Vignon, Philippe Piron, Prescillia Robert, René Papazian, Laurent Géri, Guillaume Blanc, Pascal Guitton, Christophe Guérin, Claude Bigé, Naïke Rabbat, Antoine Lefebvre, Aurélie Razazi, Keyvan Fartoukh, Muriel Mariotte, Eric Bouadma, Lila Ricard, Jean-Damien Seguin, Amélie Souweine, Bertrand Moreau, Anne-Sophie Faguer, Stanislas Mari, Arnaud Mayaux, Julien Schneider, Francis Stoclin, Annabelle Perez, Pierre Maizel, Julien Lafon, Charles Ganster, Frédérique Argaud, Laurent Girault, Christophe Barbier, François Lecuyer, Lucien Lambert, Jérôme Canet, Emmanuel Crit Care Research BACKGROUND: Pneumonia is a dreaded complication of varicella-zoster virus (VZV) infection in adults; however, the data are limited. Our objective was to investigate the clinical features, management, and outcomes of critically ill patients with VZV-related community-acquired pneumonia (VZV-CAP). METHODS: This was an observational study of patients with VZV-CAP admitted to 29 intensive care units (ICUs) from January 1996 to January 2015. RESULTS: One hundred and two patients with VZV-CAP were included. Patients were young (age 39 years (interquartile range 32–51)) and 53 (52%) were immunocompromised. Time since respiratory symptom onset was 2 (1–3) days. There was a seasonal distribution of the disease, with more cases during spring and winter time. All but four patients presented with typical skin rash on ICU admission. Half the patients received mechanical ventilation within 1 (1–2) day following ICU admission (the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO(2)/FiO(2)) = 150 (80–284), 80% with acute respiratory distress syndrome (ARDS)). Sequential Organ Failure Assessment (SOFA) score on day 1 (odds ratio (OR) 1.90 (1.33–2.70); p < 0.001), oxygen flow at ICU admission (OR 1.25 (1.08–1.45); p = 0.004), and early bacterial co-infection (OR 14.94 (2.00–111.8); p = 0.009) were independently associated with the need for mechanical ventilation. Duration of mechanical ventilation was 14 (7–21) days. ICU and hospital mortality rates were 17% and 24%, respectively. All patients were treated with aciclovir and 10 received adjunctive therapy with steroids. Compared to 60 matched steroid-free controls, patients treated with steroids had a longer mechanical ventilation duration, ICU length of stay, and a similar hospital mortality, but experienced more ICU-acquired infections. CONCLUSIONS: Severe VZV-CAP is responsible for an acute pulmonary involvement associated with a significant morbidity and mortality. Steroid therapy did not influence mortality, but increased the risk of superinfection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-017-1731-0) contains supplementary material, which is available to authorized users. BioMed Central 2017-06-07 /pmc/articles/PMC5463395/ /pubmed/28592328 http://dx.doi.org/10.1186/s13054-017-1731-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Mirouse, Adrien
Vignon, Philippe
Piron, Prescillia
Robert, René
Papazian, Laurent
Géri, Guillaume
Blanc, Pascal
Guitton, Christophe
Guérin, Claude
Bigé, Naïke
Rabbat, Antoine
Lefebvre, Aurélie
Razazi, Keyvan
Fartoukh, Muriel
Mariotte, Eric
Bouadma, Lila
Ricard, Jean-Damien
Seguin, Amélie
Souweine, Bertrand
Moreau, Anne-Sophie
Faguer, Stanislas
Mari, Arnaud
Mayaux, Julien
Schneider, Francis
Stoclin, Annabelle
Perez, Pierre
Maizel, Julien
Lafon, Charles
Ganster, Frédérique
Argaud, Laurent
Girault, Christophe
Barbier, François
Lecuyer, Lucien
Lambert, Jérôme
Canet, Emmanuel
Severe varicella-zoster virus pneumonia: a multicenter cohort study
title Severe varicella-zoster virus pneumonia: a multicenter cohort study
title_full Severe varicella-zoster virus pneumonia: a multicenter cohort study
title_fullStr Severe varicella-zoster virus pneumonia: a multicenter cohort study
title_full_unstemmed Severe varicella-zoster virus pneumonia: a multicenter cohort study
title_short Severe varicella-zoster virus pneumonia: a multicenter cohort study
title_sort severe varicella-zoster virus pneumonia: a multicenter cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463395/
https://www.ncbi.nlm.nih.gov/pubmed/28592328
http://dx.doi.org/10.1186/s13054-017-1731-0
work_keys_str_mv AT mirouseadrien severevaricellazosterviruspneumoniaamulticentercohortstudy
AT vignonphilippe severevaricellazosterviruspneumoniaamulticentercohortstudy
AT pironprescillia severevaricellazosterviruspneumoniaamulticentercohortstudy
AT robertrene severevaricellazosterviruspneumoniaamulticentercohortstudy
AT papazianlaurent severevaricellazosterviruspneumoniaamulticentercohortstudy
AT geriguillaume severevaricellazosterviruspneumoniaamulticentercohortstudy
AT blancpascal severevaricellazosterviruspneumoniaamulticentercohortstudy
AT guittonchristophe severevaricellazosterviruspneumoniaamulticentercohortstudy
AT guerinclaude severevaricellazosterviruspneumoniaamulticentercohortstudy
AT bigenaike severevaricellazosterviruspneumoniaamulticentercohortstudy
AT rabbatantoine severevaricellazosterviruspneumoniaamulticentercohortstudy
AT lefebvreaurelie severevaricellazosterviruspneumoniaamulticentercohortstudy
AT razazikeyvan severevaricellazosterviruspneumoniaamulticentercohortstudy
AT fartoukhmuriel severevaricellazosterviruspneumoniaamulticentercohortstudy
AT mariotteeric severevaricellazosterviruspneumoniaamulticentercohortstudy
AT bouadmalila severevaricellazosterviruspneumoniaamulticentercohortstudy
AT ricardjeandamien severevaricellazosterviruspneumoniaamulticentercohortstudy
AT seguinamelie severevaricellazosterviruspneumoniaamulticentercohortstudy
AT souweinebertrand severevaricellazosterviruspneumoniaamulticentercohortstudy
AT moreauannesophie severevaricellazosterviruspneumoniaamulticentercohortstudy
AT faguerstanislas severevaricellazosterviruspneumoniaamulticentercohortstudy
AT mariarnaud severevaricellazosterviruspneumoniaamulticentercohortstudy
AT mayauxjulien severevaricellazosterviruspneumoniaamulticentercohortstudy
AT schneiderfrancis severevaricellazosterviruspneumoniaamulticentercohortstudy
AT stoclinannabelle severevaricellazosterviruspneumoniaamulticentercohortstudy
AT perezpierre severevaricellazosterviruspneumoniaamulticentercohortstudy
AT maizeljulien severevaricellazosterviruspneumoniaamulticentercohortstudy
AT lafoncharles severevaricellazosterviruspneumoniaamulticentercohortstudy
AT gansterfrederique severevaricellazosterviruspneumoniaamulticentercohortstudy
AT argaudlaurent severevaricellazosterviruspneumoniaamulticentercohortstudy
AT giraultchristophe severevaricellazosterviruspneumoniaamulticentercohortstudy
AT barbierfrancois severevaricellazosterviruspneumoniaamulticentercohortstudy
AT lecuyerlucien severevaricellazosterviruspneumoniaamulticentercohortstudy
AT lambertjerome severevaricellazosterviruspneumoniaamulticentercohortstudy
AT canetemmanuel severevaricellazosterviruspneumoniaamulticentercohortstudy